Across TCGA pan-cancer cohorts, PRMT3 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRMT3 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PRMT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRMT3 expression acts as an unfavorable survival marker.

ESCA and SKCM are the cancer types where PRMT3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.124	0.703	<.001	30	view →
SKCM	DFS	Median	All	0.046	0.757	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: PRMT3 tumor-vs-normal RNA expression · all PRMT3 data types